Positive HER-2 protein expression in circulating prostate cells and micro-metastasis, resistant to androgen blockage but not diethylstilbestrol

Indian Journal of Urology

Volumn 27, Issue 2, 2011, Pages 200-207

  Murray, Nigel P ^a   Badinez, Leonardo V ^b   Dueñas, Ricardo R ^c   Orellana, Nelson ^c   Tapia, Pablo ^c  

^a UNIVERSIDAD MAYOR   (Chile)

^b Instituto Oncológico Fundación Arturo López Pérez   (Chile)

^c Department of Oral and Maxillofacial Surgery   (Chile)

Author keywords

Androgen blockade; circulating tumor cells; DES; HER 2; micrometastasis; prostate cancer

Indexed keywords

ANDROGEN; DIETHYLSTILBESTROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR BETA; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; CANCER HORMONE THERAPY; CANCER PATIENT; CELL PROLIFERATION; CELL SELECTION; CELL SURVIVAL; CENTRIFUGATION; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSTATE CANCER; PROTEIN EXPRESSION; RADICAL RESECTION; TUMOR CELL; TUMOR EMBOLISM;

EID: 79960680806     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.82838     Document Type: Article

References (20)

1. Klein LA. Prostatic carcinoma. N Engl J Med 1996;300:26-33.
2. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone resistant prostate cancer. Cancer 1993;71:1098-109. (Pubitemid 23049638)
3. Debes JD, Tindall DJ. Mechanisms of androgen refractory prostate cancer. N Engl J Med 2004;351;1488-90. (Pubitemid 39315314)
4. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, et al. Her-2(neu) expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 200;92:1918-25.
5. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 2001;7:2643-7. (Pubitemid 32911366)
6. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999;3:280-5. (Pubitemid 29124362)
7. Borgen E, Naume B, Nesland JM. Standardization of the immunocytochemical detection of cancer cells in BM and blood: Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999;5:377-88.
8. Murray NP, Calaf GM, Badinez L. Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients. Oncol Rep 2009;21:571-5.
9. Roach M 3 rd, Hanks G, Thames H Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006:65;965-74.
10. Isaacs JT. Adaptation versus selection as the mechanism responsible for the relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1982;42:5010-4.
11. Pantel K, Enzmann T, Kollermann J, Caprano J, Reithmuller G, Kollerman MW. Immunocytochemical monitoring of micrometastatic disease reduction of prostate 11. cancer cells in bone marrow by androgen deprivation. Int J Cancer 1997;71:521-5. (Pubitemid 27239359)
12. Kollermann J, Weikert S, Schostak M, Kempkensteffen C, Klienschmidt K, Rau T, et al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol 2008;26:4928-33.
13. Malkowitz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58:108-13.
14. Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, et al. Comparative studies of the estrogen receptors alpha and beta and the androgen receptor in normal human prostate glands, dysplasia and in primary and metastatic carcinoma. Am J Pathol 2001;159:79-92. (Pubitemid 33704195)
15. Horvath LG, Henshall SM, Lee CS, Head DR, Quinn DI, Mekela S, et al. Frequent loss of estrogen receptor beta expression in prostate cancer. Cancer Res 2001;61:5331-5. (Pubitemid 32694904)
16. Okegawa T, Kinlo M, Nutahara K, Higashihara E. Pretreatment serum level of HER2/neu as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 2006;13:1197-201. (Pubitemid 44410909)
17. Gravina GL, Festuccia C, Millimaggi D, Tombolini V, Dolo V, Vicentini C, et al. Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irreapective of HER2/neu expression levels. Urology 2009;74:452-7.
18. Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, et al. Response of prostate cancer to anti-HER-2/neu antibody in androgen dependent and independent human xenograft models. Cancer Res 1999;59:4761-4. (Pubitemid 29472871)
19. Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, et al. Efficacy and safety of singl agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration resistant prostate cancer after progression from taxane based therapy. J Clin Oncol 2007;25:675-81. (Pubitemid 350002923)
20. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004;60:332-7. (Pubitemid 39050653)